NeuBase Therapeutics Inc (NBSE) has released an update to notify the public and investors about an entry into a material definitive agreement.
NeuBase Therapeutics, Inc. issued Series A and Series B Common Stock Purchase Warrants to an institutional investor during a private placement and concurrent registered direct offering on June 30, 2023. Later, on October 17, 2023, the company entered an exchange agreement for the repurchase of Series B Warrants and outlined terms for Series A Warrants based on future company transactions. By January 26, 2024, NeuBase redeemed all Series A Warrants for $1,500,000 and terminated related provisions, rendering the Series A Warrants no longer outstanding.
For further insights into NBSE stock, check out TipRanks’ Stock Analysis page.
